<?xml version="1.0" encoding="UTF-8"?><rss version="2.0"
	xmlns:content="http://purl.org/rss/1.0/modules/content/"
	xmlns:wfw="http://wellformedweb.org/CommentAPI/"
	xmlns:dc="http://purl.org/dc/elements/1.1/"
	xmlns:atom="http://www.w3.org/2005/Atom"
	xmlns:sy="http://purl.org/rss/1.0/modules/syndication/"
	xmlns:slash="http://purl.org/rss/1.0/modules/slash/"
	>

<channel>
	<title>Neoadjuvant immunotherapy &#8211; BIOENGINEER.ORG</title>
	<atom:link href="https://bioengineer.org/tag/neoadjuvant-immunotherapy/feed/" rel="self" type="application/rss+xml" />
	<link>https://bioengineer.org</link>
	<description>Bioengineering</description>
	<lastBuildDate>Mon, 15 Dec 2025 15:34:33 +0000</lastBuildDate>
	<language>en-US</language>
	<sy:updatePeriod>
	hourly	</sy:updatePeriod>
	<sy:updateFrequency>
	1	</sy:updateFrequency>
	<generator>https://wordpress.org/?v=7.0</generator>

<image>
	<url>https://bioengineer.org/wp-content/uploads/2019/09/cropped-bioengineering-32x32.png</url>
	<title>Neoadjuvant immunotherapy &#8211; BIOENGINEER.ORG</title>
	<link>https://bioengineer.org</link>
	<width>32</width>
	<height>32</height>
</image> 
<site xmlns="com-wordpress:feed-additions:1">72741379</site>	<item>
		<title>Neoadjuvant Immunotherapy for Rectal Cancer: A Review</title>
		<link>https://bioengineer.org/neoadjuvant-immunotherapy-for-rectal-cancer-a-review/</link>
		
		<dc:creator><![CDATA[Bioengineer]]></dc:creator>
		<pubDate>Mon, 15 Dec 2025 15:34:02 +0000</pubDate>
				<category><![CDATA[Cancer]]></category>
		<category><![CDATA[Microsatellite stable]]></category>
		<category><![CDATA[MMR proficient]]></category>
		<category><![CDATA[Neoadjuvant immunotherapy]]></category>
		<category><![CDATA[Rectal cancer]]></category>
		<category><![CDATA[systematic review]]></category>
		<guid isPermaLink="false">https://bioengineer.org/neoadjuvant-immunotherapy-for-rectal-cancer-a-review/</guid>

					<description><![CDATA[In a groundbreaking study that could reshape the landscape of treatment for non-metastatic rectal cancer, recent findings emphasize the efficacy and safety of combining neoadjuvant therapy with immunotherapy for patients whose tumors are proficient in mismatch repair (MMR) and microsatellite stable (MSS). This systematic review and meta-analysis delves deep into the outcomes of innovative treatments, [&#8230;]]]></description>
		
		
		
		<post-id xmlns="com-wordpress:feed-additions:1">308027</post-id>	</item>
		<item>
		<title>Advances in Immunotherapy for Resectable Head-Neck Cancer</title>
		<link>https://bioengineer.org/advances-in-immunotherapy-for-resectable-head-neck-cancer/</link>
		
		<dc:creator><![CDATA[Bioengineer]]></dc:creator>
		<pubDate>Fri, 12 Dec 2025 09:52:41 +0000</pubDate>
				<category><![CDATA[Cancer]]></category>
		<category><![CDATA[Head and neck cancer]]></category>
		<category><![CDATA[immune checkpoint inhibitors** **Açıklama:** 1. **immunotherapy:** Makalenin ana konusu ve devrim niteliğindeki gelişmelerin odağı. 2. **head and neck cancer:** Araştırmanın spes]]></category>
		<category><![CDATA[Makale içeriğine ve ana temalarına göre en uygun 5 etiket: **immunotherapy]]></category>
		<category><![CDATA[Neoadjuvant immunotherapy]]></category>
		<category><![CDATA[resectable]]></category>
		<guid isPermaLink="false">https://bioengineer.org/advances-in-immunotherapy-for-resectable-head-neck-cancer/</guid>

					<description><![CDATA[In recent years, the landscape of cancer treatment has undergone a revolutionary transformation with the introduction and advancement of immunotherapy. Among the various malignancies responsive to these novel approaches, head and neck squamous cell carcinoma (HNSCC) stands out due to its distinct biological behavior and historically poor outcomes in advanced stages. Groundbreaking research conducted by [&#8230;]]]></description>
		
		
		
		<post-id xmlns="com-wordpress:feed-additions:1">306629</post-id>	</item>
		<item>
		<title>Neoadjuvant Immunotherapy Advances in MMR-Proficient Colon Cancer</title>
		<link>https://bioengineer.org/neoadjuvant-immunotherapy-advances-in-mmr-proficient-colon-cancer/</link>
		
		<dc:creator><![CDATA[Bioengineer]]></dc:creator>
		<pubDate>Mon, 20 Oct 2025 16:17:14 +0000</pubDate>
				<category><![CDATA[Technology]]></category>
		<category><![CDATA[Dual checkpoint blockade]]></category>
		<category><![CDATA[Major pathological response]]></category>
		<category><![CDATA[MMR-proficient colon cancer]]></category>
		<category><![CDATA[Neoadjuvant immunotherapy]]></category>
		<category><![CDATA[NICHE clinical trial]]></category>
		<guid isPermaLink="false">https://bioengineer.org/neoadjuvant-immunotherapy-advances-in-mmr-proficient-colon-cancer/</guid>

					<description><![CDATA[In recent years, immune checkpoint blockade (ICB) has revolutionized the treatment landscape for various malignancies, marking a new era in oncology. Therapies targeting immune checkpoints like PD-1 and CTLA-4 have demonstrated remarkable success in cancers such as melanoma, non-small cell lung cancer, and renal cell carcinoma. However, a significant challenge persists with colorectal cancer, particularly [&#8230;]]]></description>
		
		
		
		<post-id xmlns="com-wordpress:feed-additions:1">283863</post-id>	</item>
	</channel>
</rss>
